title: [Functional and motor gastrointestinal disorders].
abstract: This article discusses the most interesting studies on functional and motor gastrointestinal disorders presented at Digestive Diseases Week (DDW), 2015. Researchers are still seeking biomarkers for irritable bowel syndrome and have presented new data. One study confirmed that the use of low-dose antidepressants has an antinociceptive effect without altering the psychological features of patients with functional dyspepsia. A contribution that could have immediate application is the use of transcutaneous electroacupuncture, which has demonstrated effectiveness in controlling nausea in patients with gastroparesis. New data have come to light on the importance of diet in irritable bowel syndrome, although the effectiveness of a low-FODMAP diet seems to be losing momentum with time. Multiple data were presented on the long-term efficacy of rifaximin therapy in patients with irritable bowel syndrome and diarrhoea. In addition, among other contributions, and more as a curiosity, a study evaluated the effect of histamine in the diet of patients with irritable bowel syndrome.
authors.affiliation: Servicio de Aparato Digestivo, Instituto de Trastornos Funcionales y Motores Digestivos, Centro Médico Teknon, Barcelona, España.
authors.forename: Fermín
authors.initials: F
authors.lastname: Mearin
authors.affiliation: Servicio de Aparato Digestivo, Hospital Clínico Universitario San Carlos, Madrid, España.
authors.forename: Enrique
authors.initials: E
authors.lastname: Rey
authors.affiliation: Servicio de Aparato Digestivo, Instituto de Trastornos Funcionales y Motores Digestivos, Centro Médico Teknon, Barcelona, España. Electronic address: agustin.balboa@gmail.com.
authors.forename: Agustín
authors.initials: A
authors.lastname: Balboa
mesh_terms: D000928:Antidepressive Agents / Q000627:therapeutic use; D015415:Biomarkers; D003248:Constipation / Q000503:physiopathology / Q000523:psychology / Q000628:therapy; D003967:Diarrhea / Q000503:physiopathology / Q000523:psychology / Q000628:therapy; D004040:Dietary Carbohydrates / Q000009:adverse effects; D004043:Dietary Fiber / Q000627:therapeutic use; D004238:Diverticulitis / Q000517:prevention & control; D004415:Dyspepsia / Q000188:drug therapy / Q000503:physiopathology / Q000523:psychology; D015671:Electroacupuncture; D005285:Fermentation; D005765:Gastrointestinal Agents / Q000627:therapeutic use; D005767:Gastrointestinal Diseases / Q000503:physiopathology / Q000523:psychology / Q000628:therapy; D005769:Gastrointestinal Motility / Q000502:physiology; D018589:Gastroparesis / Q000473:pathology / Q000503:physiopathology / Q000628:therapy; D006632:Histamine / Q000009:adverse effects; D006801:Humans; D056885:Interstitial Cells of Cajal / Q000473:pathology; D043183:Irritable Bowel Syndrome / Q000178:diet therapy / Q000188:drug therapy / Q000503:physiopathology / Q000523:psychology; D016032:Randomized Controlled Trials as Topic; D012294:Rifamycins / Q000627:therapeutic use; D000078262:Rifaximin
chemical_list: D000928:Antidepressive Agents; D015415:Biomarkers; D004040:Dietary Carbohydrates; D004043:Dietary Fiber; D005765:Gastrointestinal Agents; D012294:Rifamycins; D006632:Histamine; D000078262:Rifaximin
keywords: Dispepsia funcional; Estreñimiento funcional; Functional constipation; Functional dyspepsia; Functional gastrointestinal disorders; Gastroparesia; Gastroparesis; Irritable bowel syndrome; Síndrome del intestino irritable; Trastornos funcionales digestivos